GYRE
Gyre TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Hydronidone now has a concrete China regulatory path after priority review and NDA submission, and Cullgen adds pipeline breadth and PRC development capability while Q1 revenue still grew modestly.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Cullgen integration and the ongoing portfolio review could distract management and delay capital-allocation payoffs.
Momentum
61
Value
58
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.00 · Bull $11.50 · Bear $3.75
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $18.67
Why
Momentum61 · Δ7d -
Value58 · Δ7d -0.1
Sentiment54 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
61
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.1
Sentiment
54
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 61.2 / Value 58.5 / Sentiment 53.8
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$674.51M
Beta
1.89
Shares Out
111.49M
P/E (TTM)
122.7
P/S (TTM)
6.71
P/FCF (TTM)
533.62
Rev YoY
+2.1%
EPS YoY
-2334.9%
Gross Margin
+95.1%
Op Margin
+11.2%
Net Debt
-$51.49M
Current Ratio
4.64
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology